SuperworthBriaCell Therapeutics BCTX
- Market cap
- $29.9M
- PE
- n/m
- one or more of the four quarters through 2026-04-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $5.2M+63% | $6.9M+111% | $8.3M+170% | $7.7M+98% | $4.4M−15% | $3.7M−47% | $5.7M−31% | $4.8M−37% | $7.1M+61% | $6.7M+82% | $6.1M+7% | $6M+24% |
| SG&A | $2.5M+23% | $1.6M−23% | $1.6M+10% | $1.6M−14% | $1.4M−46% | $1.5M−10% | $1.5M−6% | $1.5M−3% | $1.4M+6% | $1.6M+10% | $1.5M−1% | $1.7M+9% |
| −$7.7M+47% | −$8.5M+57% | −$9.8M+119% | −$9.2M+63% | −$5.8M−25% | −$5.2M−39% | −$7.2M−27% | −$6.3M−31% | −$8.6M+48% | −$8.3M+62% | −$7.5M+5% | −$7.6M+20% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $37K | $0 | n/a | n/a | $29.6K−20% |
| Net income | −$2.4M+437% | $6M | −$11.3M−5% | $1.7M | −$1.2M−50% | −$5.8M | −$6.3M−44% | −$6.1M | −$8.1M+566% | −$8.2M+41% | −$7.2M+15% | −$7.2M+17% |
| −$22.50+400% | −$75.00+614% | −$106.40−8% | $16.10 | −$12.00−47% | −$32.67−56% | −$23.31−78% | −$16.42 | n/a | −$4.35−87% | −$2.58−89% | −$0.99−94% | |
| 106.1K+3% | 111.2K+8% | 106.5K+3% | 106.5K+3% | 119.1K+12% | 177.6K+60% | 270K+153% | 373.1K+250% | n/a | 1.9M+961% | 2.8M+938% | 7.3M+1844% |
Net income: Q2 FY22 and Q2 FY23: not printed by the filing, worked out from its own lines.
EPS, diluted: 4 periods, Q1 FY22 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY22: share-days: the 6-month average less the second quarter's. 3 periods, Q4 FY22 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest BriaCell Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BCTXBriaCell Therapeutics | $29.9M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $69M | 11.1× | 14.5× | 0.4× | −3% | 3.7% |
More on BriaCell Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .